Valuation: SANA AB

Market Cap 1.77B 183M 160M 149M 137M 257M 17.63B 261M 692M 8.63B 685M 671M 30.14B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.77B 183M 160M 149M 137M 257M 17.63B 261M 692M 8.63B 685M 671M 30.14B EV / Sales 2026 *
6.62x
EV / Sales 2027 * 4.56x
Free-Float
81.6%
Yield 2026 *
-
Yield 2027 * -
1 day-2.59%
1 week-1.76%
Current month-2.29%
1 month-0.47%
3 months-10.23%
6 months-48.86%
Current year-39.58%
1 week 12.69
Extreme 12.69
13.5
1 month 12.54
Extreme 12.54
13.83
Current year 12.25
Extreme 12.25
28.3
1 year 8.03
Extreme 8.03
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 01/03/2025
Chief Executive Officer 66 30/04/2022
Chief Tech/Sci/R&D Officer 68 01/01/2014
Director TitleAgeSince
Chairman 71 30/04/2022
Director/Board Member 68 01/01/2015
Director/Board Member 46 19/01/2018
Date Insider Type Main position Quantity % Market Cap.
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
29/12/25 Sell

Chief Executive Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%-1.76%+42.65%+35.13% 182M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.20%+0.97%+40.43%+153.98% 24.03B
Weighted average by Cap. -0.87%+2.09%+39.70%+133.42%

Financials

2026 *2027 *
Net sales 267M 27.57M 24.21M 22.52M 20.66M 38.87M 2.66B 39.45M 104M 1.3B 103M 101M 4.55B 388M 40.04M 35.16M 32.71M 30.01M 56.45M 3.87B 57.3M 152M 1.89B 150M 147M 6.61B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
43
Date Price Change Volume
24/07/26 SEK 12.81 -2.59% 274,514
23/07/26 SEK 13.15 -0.68% 164,092
22/07/26 SEK 13.24 +1.61% 310,266
21/07/26 SEK 13.03 +0.70% 253,062
20/07/26 SEK 12.94 -0.77% 202,188

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock